Join Lipocine for a virtual KOL event focused on the continued unmet needs in postpartum depression (PPD) and the potential role of LPCN 1154 (BRLIZIO™) as a differentiated treatment option for women with PPD.

The event will feature Kristina M. Deligiannidis, MD (Zucker Hillside Hospital, Northwell Health) and Rakesh Jain, MD, MPH (Texas Tech University), who will join Lipocine management to discuss the current PPD treatment landscape and persistent gaps in care despite recent therapeutic approvals.

The discussion will also review clinical development progress for LPCN 1154, including the Phase 3 topline results and subgroup analyses and next steps, with the KOLs providing their perspectives on the clinical relevance of the findings and how the data may inform the potential positioning of LPCN 1154 in the depression treatment paradigm.

A live question and answer session will follow the formal presentations.

*Brand name conditionally approved by the FDA